Objective: To analyze the spatial distribution of mortality by leukemia in the population, looking for clusters, and to establish an association with the level of industrialization.
Method: The study was carried out in 43 state regions of the state of São Paulo, Brazil, in the period between 1991 and 1995. It was created an Index of Industrialization-Related Leukemia (IIRL) based on number of manufactures and industrial jobs per 100,000 inhabitants, fiscal aggregated value, diversity of industry activities and presence of manufactures that poses potential risk exposure for leukemia. IIRL was classified in five categories. Standardized leukemia mortality rates were established for each region, classified in five categories, plotted in five different colors and compared to the IIRL map.
Results: The most industrialized regions in the state of São Paulo are Campinas, Piracicaba, Jundiaí, Sorocaba and São Paulo. There was no relationship between mortality by any leukemia type and industrialization. The region of Jales showed the highest standardized mortality rates by leukemia.
Conclusions: Mortality by leukemia had a homogeneous distribution in the state of São Paulo and no association with the level of industrialization. However, aspects related to the epidemiological method applied--ecological study, mortality by leukemia as a parameter to study a disease which prognosis has changed in the last decades--limit the results interpretation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/s0034-89102002000400005 | DOI Listing |
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-matched donors is the gold standard. However, haploidentical stem cell transplantation using posttransplant cyclophosphamide (PTCY-haplo) and cord blood transplants (CBTs) are alternatives when HLA-matched donors are unavailable. Using the Japanese Registry data, we evaluated the impact of haploidentical donor age on posttransplant outcomes by comparing PTCY-haplo and CBT.
View Article and Find Full Text PDFFront Immunol
March 2025
State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Introduction: Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effects remains unclear as induction therapy for AML.
View Article and Find Full Text PDFInt J Mol Sci
March 2025
Department of Life Science, Graduate School, CHA University, Seongnam-si 13488, Gyeonggi-do, Republic of Korea.
Sialic acids serve as crucial terminal sugars on glycoproteins or glycolipids present on cell surfaces. These sugars are involved in diverse physiological and pathological processes through their interactions with carbohydrate-binding proteins, facilitating cell-cell communication and influencing the outcomes of bacterial and viral infections. The role of hypersialylation in tumor growth and metastasis has been widely studied.
View Article and Find Full Text PDFCancers (Basel)
March 2025
Department of Endocrinology and Nutrition, Quironsalud Malaga Hospital, 29004 Malaga, Spain.
: Haematologic cancers, such acute leukaemia, lymphoma, and multiple myeloma, are associated with high morbidity and mortality rates, often exacerbated by malnutrition and functional decline. This study aims to evaluate the prognostic value of bioimpedance phase angle (PhA) and hand grip strength (HGS) as nutritional and clinical markers for predicting 12-month mortality in hospitalized patients with haematologic cancers. : A retrospective observational study was conducted on 121 patients admitted to Hospital Quironsalud Málaga between January 2019 and June 2021.
View Article and Find Full Text PDFJ Natl Compr Canc Netw
March 2025
Fred Hutchinson Cancer Center, University of Washington, Seattle, WA.
Infectious complications are among the leading causes of mortality in chronic lymphocytic leukemia (CLL). Over the past decade, several advances have been made in treating CLL through inhibition of Bruton tyrosine kinase and the antiapoptotic protein BCL-2. As mortality from CLL progression is expected to decline in the next several years, mortality from severe infections is anticipated to increase.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!